Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 6 of 116

  1. CA209-8HW

    Bristol-Myers Squibb Australia Pty Ltd

    Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient Metastatic Colorectal Cancer (dMMR)

    phase 3 small molecule active

    1 trial

  2. CA209-8Y8

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Renal Cell Carcinoma with Intermediate- or Poor-Risk Factors

    phase 3 small molecule active

    1 trial

  3. CA209-901

    Bristol-Myers Squibb Australia Pty Ltd

    Untreated Unresectable or Metastatic Urothelial Cancer

    phase 3 small molecule active

    1 trial

  4. CA209-9DW

    Bristol-Myers Squibb Australia Pty Ltd

    Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Carcinoma

    phase 3 small molecule active

    1 trial

  5. CA209-9DX

    Bristol-Myers Squibb Australia Pty Ltd

    Hepatocellular Carcinoma

    phase 3 small molecule active

    1 trial

  6. CA209-9ER

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced or Metastatic Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

  7. CA209-9LA

    Bristol-Myers Squibb Australia Pty Ltd

    Stage IV Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  8. CA224-047

    Bristol-Myers Squibb Australia Pty Ltd

    Previously Untreated Metastatic or Unresectable Melanoma

    phase 3 small molecule active

    1 trial

  9. CA224-098

    Bristol-Myers Squibb Australia Pty Ltd

    Participants with completely resected Stage III or Stage IV melanoma

    phase 3 small molecule active

    1 trial

  10. CA224-123

    Bristol-Myers Squibb Australia Pty Ltd

    Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  11. CA2241093

    Bristol-Myers Squibb Australia Pty Ltd

    Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  12. CA239-0004

    Bristol-Myers Squibb Australia Pty Ltd

    Locally Advanced or Metastatic Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  13. CA240-0029

    Bristol-Myers Squibb Australia Pty Ltd

    metastatic non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  14. CA240-0030

    Bristol-Myers Squibb Australia Pty Ltd

    Untreated Metastatic Pancreatic Ductal Adenocarcinoma

    phase 3 small molecule active

    1 trial

  15. CA244-0008

    Bristol-Myers Squibb Australia Pty Ltd

    Breast cancer, Triple-negative breast cancer

    phase 3 small molecule active

    1 trial

  16. CA244-0010

    Bristol-Myers Squibb Australia Pty Ltd

    EGFR-mutated Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  17. CA2440012

    Bristol-Myers Squibb Australia Pty Ltd

    Metastatic urothelial cancer

    phase 3 small molecule active

    1 trial

  18. CA245-0001

    Bristol-Myers Squibb Australia Pty Ltd

    Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial

  19. CA2660001

    Bristol-Myers Squibb Australia Pty Ltd

    Unresectable Stage III non-small cell lung cancer without progression

    phase 3 small molecule active

    1 trial

  20. CA2660002

    Bristol-Myers Squibb Australia Pty Ltd

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  21. CA2660003

    Bristol-Myers Squibb Australia Pty Ltd

    Untreated, Unresectable or Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  22. CA2660004

    Bristol-Myers Squibb Australia Pty Ltd

    Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

    phase 3 small molecule active

    1 trial

  23. CAAA601A62301

    Novartis Pharmaceuticals

    Gastroenteropancreatic neuroendocrine tumor (GEP-NET)

    phase 3 small molecule active

    1 trial

  24. CAAA617B12302

    Novartis Pharmaceuticals

    PSMA-positive metastatic castration-resistant prostate cancer

    phase 3 small molecule active

    1 trial

  25. CAAA617C12301

    Novartis Pharmaceuticals

    PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC)

    phase 3 small molecule active

    1 trial

  26. CAAA617D12302

    Novartis Pharmaceuticals

    Oligometastatic prostate cancer (OMPC)

    phase 3 small molecule active

    1 trial

  27. CABAZITAXEL

    Sanofi Pasteur

    Prostate Cancer Metastatic

    phase 3 small molecule completed

    1 trial

  28. CABL001A2001B

    Novartis Pharmaceuticals

    chronic myelogenous leukemia (CML) or Philadelphia Chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

    phase 3 small molecule active

    1 trial

  29. CABL001J12301

    Novartis Pharmaceuticals

    Chronic Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  30. CABL001J12302

    Novartis Pharmaceuticals

    Chronic Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  31. CANAKINUMAB, PEMETREXED

    Novartis Pharmaceuticals

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  32. CAPECITABINE

    Disc Medicine

    Salivary Duct Carcinoma

    phase 3 small molecule active

    1 trial

  33. CAPECITABINE for Locally advanced stage II/III rectal cancer

    Fondazione Telethon ETS

    Locally advanced stage II/III rectal cancer

    phase 3 small molecule active

    1 trial

  34. CBYL719C2303

    Novartis Pharmaceuticals

    Hormone receptor positive, HER2-negative advanced breast cancer

    phase 3 small molecule active

    1 trial

  35. CBYL719K12301

    Novartis Pharmaceuticals

    Platinum-resistant or refractory, high-grade serous ovarian cancer with no germline BRCA mutation

    phase 3 small molecule active

    1 trial

  36. CCTL019H2301

    Novartis Pharmaceuticals

    Adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma

    phase 3 small molecule active

    1 trial

  37. CETUXIMAB

    Disc Medicine

    oral squamous cell carcinoma

    phase 3 small molecule active

    1 trial

  38. CG0070 Adenovirus Vector

    CG Oncology

    Transitional Cell Carcinoma

    phase 3 mab terminated

    1 trial

  39. CGT9486 plus sunitinib

    Cogent Biosciences

    Advanced Gastrointestinal Stromal Tumors

    phase 3 small molecule active

    1 trial

  40. CISPLATIN

    Ningbo Cancer Hospital

    Ovarian epithelial cancer : intraperitoneal resectable relapse

    phase 3 small molecule active

    1 trial

  41. CISPLATIN, CARBOPLATIN

    Cardiff Oncology

    Human papillomavirus (HPV)-positive oropharyngeal cancer

    phase 3 small molecule active

    1 trial

  42. CJDQ443B12301

    Novartis Pharmaceuticals

    Advanced non-small cell lung cancer harboring the KRAS G12C mutation

    phase 3 small molecule active

    1 trial

  43. CL3-95005-006

    The George Institute

    Metastatic colorectal cancer

    phase 3 small molecule active

    1 trial

  44. CL3-95031-007

    The George Institute

    Locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 or 2 systemic treatment regimens

    phase 3 small molecule active

    1 trial

  45. CLEE011O12001

    Novartis Pharmaceuticals

    HR-positive HER-2- negative Breast Cancer

    phase 3 small molecule active

    1 trial

  46. CLEE011O12301C

    Novartis Pharmaceuticals

    hormone receptor (HR)-positive, HER2-negative, early breast cancer (EBC).

    phase 3 small molecule active

    1 trial

  47. CLIN2001UCM301

    STEBA Biotech S.A

    Low Grade Upper Tract Urothelial Cancer

    phase 3 small molecule active

    1 trial

  48. CMF regimen

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 3 small molecule active

    2 trials

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.